KR102125594B1 - 면역 조절 - Google Patents

면역 조절 Download PDF

Info

Publication number
KR102125594B1
KR102125594B1 KR1020157029396A KR20157029396A KR102125594B1 KR 102125594 B1 KR102125594 B1 KR 102125594B1 KR 1020157029396 A KR1020157029396 A KR 1020157029396A KR 20157029396 A KR20157029396 A KR 20157029396A KR 102125594 B1 KR102125594 B1 KR 102125594B1
Authority
KR
South Korea
Prior art keywords
ara
arg
glu
gln
peanut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157029396A
Other languages
English (en)
Korean (ko)
Other versions
KR20160002771A (ko
Inventor
폴 마이클 하울리
Original Assignee
세멘티스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세멘티스 리미티드 filed Critical 세멘티스 리미티드
Publication of KR20160002771A publication Critical patent/KR20160002771A/ko
Application granted granted Critical
Publication of KR102125594B1 publication Critical patent/KR102125594B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020157029396A 2013-03-15 2014-03-17 면역 조절 Active KR102125594B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361852239P 2013-03-15 2013-03-15
US61/852,239 2013-03-15
PCT/AU2014/000286 WO2014138824A1 (en) 2013-03-15 2014-03-17 Immune modulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033558A Division KR102212253B1 (ko) 2013-03-15 2014-03-17 면역 조절

Publications (2)

Publication Number Publication Date
KR20160002771A KR20160002771A (ko) 2016-01-08
KR102125594B1 true KR102125594B1 (ko) 2020-06-24

Family

ID=51535630

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157029396A Active KR102125594B1 (ko) 2013-03-15 2014-03-17 면역 조절
KR1020197033558A Active KR102212253B1 (ko) 2013-03-15 2014-03-17 면역 조절

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197033558A Active KR102212253B1 (ko) 2013-03-15 2014-03-17 면역 조절

Country Status (16)

Country Link
US (2) US11173206B2 (enExample)
EP (2) EP3685853A1 (enExample)
JP (2) JP6549042B2 (enExample)
KR (2) KR102125594B1 (enExample)
CN (2) CN105163756A (enExample)
AU (1) AU2014231734B2 (enExample)
CA (1) CA2906735C (enExample)
DK (1) DK2968528T3 (enExample)
ES (1) ES2909750T3 (enExample)
HK (1) HK1219436A1 (enExample)
IL (1) IL241596B (enExample)
MY (1) MY193724A (enExample)
NZ (1) NZ630642A (enExample)
RU (2) RU2709771C2 (enExample)
SG (1) SG11201507657QA (enExample)
WO (1) WO2014138824A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2914286T3 (da) 2012-10-30 2021-11-08 Aravax Pty Ltd Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf
RU2709771C2 (ru) 2013-03-15 2019-12-19 Симентис Лимитед Иммунная модуляция
KR20160075532A (ko) 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 신규한 면역치료제 조성물 및 이의 용도
CA3265584A1 (en) 2016-08-19 2025-03-14 Sementis Ltd VIRUS VACCINES
IL304904A (en) * 2021-02-01 2023-10-01 St Phi Therapeutics Co Ltd Target protein degradation system and its use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104581A1 (en) 2006-03-14 2007-09-20 Paul-Ehrlich-Institut Bundesamt Für Sera Und Impfstoffe Use of recombinant modified vaccinia virus ankara (mva) for the treatment of type 1 hypersensitivity in a living animal including humans

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US5773705A (en) 1992-12-31 1998-06-30 Wisconsin Alumni Research Foundation Ubiquitin fusion protein system for protein production in plants
WO2001040264A2 (en) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Peptide antigens
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
EP2253709B1 (en) * 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
CA2527102A1 (en) * 2003-07-10 2005-01-20 Cytos Biotechnology Ag Packaged virus-like particles
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
CN100374152C (zh) * 2005-12-23 2008-03-12 中国农业大学 一种过敏性反应抑制剂
EP2153841B2 (en) * 2008-08-15 2015-11-11 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
GB201104537D0 (en) * 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
RU2709771C2 (ru) * 2013-03-15 2019-12-19 Симентис Лимитед Иммунная модуляция

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104581A1 (en) 2006-03-14 2007-09-20 Paul-Ehrlich-Institut Bundesamt Für Sera Und Impfstoffe Use of recombinant modified vaccinia virus ankara (mva) for the treatment of type 1 hypersensitivity in a living animal including humans

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Liu, Y. et al., J Allergy Clin Immunol. 2013, 131(1):213-221.e105 Epub 2012 Nov 27

Also Published As

Publication number Publication date
RU2709771C2 (ru) 2019-12-19
EP2968528B1 (en) 2022-02-23
EP2968528A4 (en) 2016-10-12
EP2968528A1 (en) 2016-01-20
JP2019134707A (ja) 2019-08-15
SG11201507657QA (en) 2015-10-29
KR20160002771A (ko) 2016-01-08
US20160030552A1 (en) 2016-02-04
CN105163756A (zh) 2015-12-16
RU2018121086A (ru) 2019-03-05
AU2014231734A1 (en) 2015-10-08
NZ630642A (en) 2016-01-29
KR20190130665A (ko) 2019-11-22
EP3685853A1 (en) 2020-07-29
RU2015144308A (ru) 2017-04-20
KR102212253B1 (ko) 2021-02-04
IL241596B (en) 2018-05-31
US20220088189A1 (en) 2022-03-24
MY193724A (en) 2022-10-27
JP6549042B2 (ja) 2019-07-24
ES2909750T3 (es) 2022-05-10
JP2016513963A (ja) 2016-05-19
CA2906735C (en) 2020-03-24
RU2018121086A3 (enExample) 2019-03-05
CA2906735A1 (en) 2014-09-18
HK1219436A1 (zh) 2017-04-07
US11173206B2 (en) 2021-11-16
CN109517842A (zh) 2019-03-26
AU2014231734B2 (en) 2018-03-15
WO2014138824A1 (en) 2014-09-18
RU2662927C2 (ru) 2018-07-31
DK2968528T3 (da) 2022-03-28

Similar Documents

Publication Publication Date Title
US20220088189A1 (en) Immune modulation
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN112876570A (zh) 非洲猪瘟病毒疫苗及其制备方法
AU2019349036A1 (en) Immune composition, preparation method therefor, and application thereof
CN106232813B (zh) 预防减蛋综合征(eds)的疫苗
EP4205762A1 (en) Improved dna vaccine for sars-cov-2
EP4549452A1 (en) Pharmaceutical composition for resisting infection with sars-cov-2 or mutant thereof, and combined drug thereof
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN111925994B (zh) 一种dp71l基因缺失的重组非洲猪瘟病毒及其制备方法和应用
CN113637695B (zh) 靶向刺激体液免疫和细胞免疫的新冠病毒mRNA疫苗
HK40000107A (en) Immune modulation
US20250177514A1 (en) Coronavirus antigen variants
CN100535002C (zh) 重组结核杆菌抗原多表位肽及其构建方法与用途
WO2023013787A1 (ja) Ｓｎａｒｅを活用した核酸構築物
CN117659140A (zh) 新冠病毒hla-a2限制性表位肽及应用
JP2007502602A (ja) 前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター
CN117964720A (zh) HLA-A*02:01限制性SARS-CoV-2 T细胞表位肽及其应用
CN117903264A (zh) 新冠病毒SARS-CoV-2 HLA-A2限制性表位肽及应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180723

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20180723

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181126

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190528

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181126

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190528

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190321

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190815

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190716

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190528

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190321

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20181126

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191113

PJ0201 Trial against decision of rejection

Patent event date: 20191113

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20190815

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20190528

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20200224

Appeal identifier: 2019101003749

Request date: 20191113

J301 Trial decision

Free format text: TRIAL NUMBER: 2019101003749; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20191113

Effective date: 20200224

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20200224

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20191113

Decision date: 20200224

Appeal identifier: 2019101003749

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20200327

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20200303

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200616

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200616

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240430

Start annual number: 5

End annual number: 5